Extrachromosomal circular DNA (eccDNA) undergoes self-aggregation and phase separation with HOXD13 to confer chemotherapy resistance

Cancer is a disease of genetic chaos. Inside a tumor, the instructions for life, which are usually neatly packaged on long strands called chromosomes, can break apart and reassemble in wild, unpredictable ways. One of the most disruptive outcomes of this chaos is the formation of tiny, circular loops of DNA that float freely outside the main chromosomes. Scientists call these extrachromosomal circular DNA, or eccDNA. Unlike the stable DNA in our chromosomes, these loops can copy themselves rapidly and in huge numbers, often carrying genes that help cancer cells grow or survive treatment. For years, researchers knew these loops existed and suspected they were dangerous, but the exact mechanism by which they hijack a cell's machinery to cause drug resistance remained a mystery. Understanding how these rogue loops operate is critical because it could reveal new ways to stop tumors from becoming untreatable.

A team of researchers at the Tianjin Medical University Cancer Institute and Hospital has now uncovered a specific pathway where these circular DNA loops team up with a protein to shield cancer cells from chemotherapy. Focusing on esophageal squamous cell carcinoma, a type of cancer that affects the food pipe, the scientists discovered that these circular DNA loops do not just sit idle. Instead, they clump together and interact with a specific protein called HOXD13. This interaction triggers the formation of liquid-like droplets inside the cell, a process known as phase separation. Think of these droplets as tiny, temporary bubbles that gather specific molecules together to get work done. In this case, the droplets act as a protective shield, helping the cancer cells survive the toxic effects of cisplatin, a common chemotherapy drug. The study shows that when these loops are present, they force the HOXD13 protein to gather into these droplets, which then travel into the cell's command center, the nucleus, to turn on genes that promote survival and resistance.

The researchers began by comparing cancer cells that had become resistant to cisplatin with those that remained sensitive. They found that the resistant cells contained significantly higher amounts of these circular DNA loops. To prove that these loops were the cause of the resistance, they isolated the loops from resistant cells and inserted them into sensitive cancer cells. The result was immediate: the sensitive cells suddenly became resistant to the drug. Conversely, when they removed the protein HOXD13 from the cells, the protective effect of the DNA loops disappeared, and the cells became sensitive to the drug again. This confirmed that the loops and the protein work together as a team to drive the disease forward.

To understand how this team works, the scientists looked closer at the behavior of the HOXD13 protein. They observed that when cells were exposed to cisplatin or other stressors, the protein would gather into distinct, fluid droplets. These droplets behaved like liquid, merging and moving, rather than forming solid clumps. The researchers found that the presence of the circular DNA loops was essential for this gathering to happen. When they treated the cells with an enzyme that digests DNA, the droplets dissolved, and the protein scattered. Furthermore, they discovered that the circular loops could bind directly to the HOXD13 protein in a test tube, and this binding was strengthened by the presence of the chemotherapy drug itself. This suggests that the drug, intended to kill the cancer, inadvertently helps the cancer build its defense by encouraging the DNA loops and the protein to stick together.

Once these droplets formed, they needed to get into the nucleus to do their damage. The team identified a specific transport protein, KPNB1, that acts as a shuttle, carrying the HOXD13 droplets from the main body of the cell into the nucleus. When the researchers blocked this shuttle, the droplets stayed stuck in the cytoplasm and could not trigger the resistance genes. Inside the nucleus, the HOXD13 droplets helped turn on a suite of genes related to inflammation and cancer growth, effectively reprogramming the cell to ignore the chemotherapy. The study also showed that these loops interact with another major regulator of inflammation, NF-κB, further amplifying the cell's ability to survive stress.

The most promising finding of the study is a potential new way to treat these resistant tumors. Since the circular DNA loops are the starting point of this entire defense mechanism, the researchers tested whether removing them would make the cancer vulnerable again. They treated the resistant cells and tumor-bearing mice with DNase I, an enzyme that breaks down DNA. When combined with cisplatin, this treatment cleared the circular loops from the cells. Without the loops, the HOXD13 protein could not form its protective droplets, and the cancer cells lost their resistance. In mice with tumors, the combination of the enzyme and the chemotherapy drug shrank the tumors significantly more than either treatment alone and caused much more damage to the cancer cells' DNA.

This work provides a clear map of how a specific type of genetic debris can drive cancer resistance. It shows that extrachromosomal circular DNA acts as a catalyst, gathering a key protein into liquid droplets that travel to the cell's command center to switch on survival genes. By targeting the removal of these DNA loops, it may be possible to strip cancer cells of their defenses and restore the effectiveness of standard chemotherapy. The study does not claim this is a cure, but it offers a concrete, actionable strategy to overcome a major hurdle in treating esophageal cancer and potentially other cancers where these circular loops play a role.